1986
DOI: 10.1159/000285140
|View full text |Cite
|
Sign up to set email alerts
|

New Pharmacological Developments in Antidepressants

Abstract: The new pharmacological developments in antidepressants are reviewed with particular reference to MAOIs. Combining an MAOI with amitriptyline reduces the risk of a tyramine-induced rise of blood pressure but does not eliminate the risk which is comparable to that of one of the new reversible MAO-A inhibitors (CGP 11305A).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2006
2006
2009
2009

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 16 publications
0
2
0
Order By: Relevance
“…given the known effects of monoamine oxidase inhibitors on psychiatric disorders such as major depression (83).…”
Section: Nadph Oxidase-derived Ros Signaling In the Brainmentioning
confidence: 99%
“…given the known effects of monoamine oxidase inhibitors on psychiatric disorders such as major depression (83).…”
Section: Nadph Oxidase-derived Ros Signaling In the Brainmentioning
confidence: 99%
“…These data indicate that there may be as many as three different sources of ROS in cerebellar granule cells. Further investigation into the potential role of monoamine oxidase in ROS generation during synaptic plasticity may lead to important insights regarding psychiatric disease, given the known effects of monoamine oxidase inhibitors on psychiatric disorders such as major depression (83).…”
Section: Monoamine Oxidase and Cyclooxygenasementioning
confidence: 99%